| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| David Shook | Med | 2026-09-10 | 500 | $12.70 | $6.35kSell |
| Gary K. Lee | CSci | 2026-08-21 | 1,457 | $15.54 | $22.64kSell |
| Lynn Seely | CEO;Pres | 2026-08-21 | 9,589 | $15.54 | $149.01kSell |
| Stephen J. Hill | COO | 2026-08-21 | 989 | $15.54 | $15.37kSell |
| Gary K. Lee | CSci | 2026-08-10 | 131 | $14.34 | $1.88kSell |
| Lynn Seely | CEO;Pres | 2026-08-10 | 390 | $14.34 | $5.59kSell |
| Stephen J. Hill | COO | 2026-08-10 | 89 | $14.34 | $1.28kSell |
| Veronica Sanchez Bulis | Ctrl;VP | 2026-08-10 | 621 | $14.34 | $8.91kSell |
| Cellular Therapeuti Innovative | 10% Owner | 2026-07-17 | 10 | $13.70 | $137.00Sell |
| Innovative Cellular Therapeutics Holdings Ltd | 10% Owner | 2026-07-17 | 10 | $13.70 | $137.00Sell |
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Robert Nelsen | 222.89% | 54,619,074 | $601.36M | Insider |
| Arch Venture Partners IX LLC | 159.74% | 39,143,667 | $430.97M | Insider |
| Glaxosmithkline PLC | 123.46% | 30,253,189 | $333.09M | Insider |
| Richard Klausner | 23.02% | 5,641,764 | $62.12M | Insider |
| Hans Edgar Bishop | 19.12% | 4,685,614 | $51.59M | Insider |
| Cellular Therapeuti Innovative | 11.66% | 2,857,480 | $31.46M | Insider |
| Innovative Cellular Therapeutics Holdings Ltd | 11.66% | 2,857,480 | $31.46M | Insider |
| Cellular Therapeutics Holding Innovative | 11.32% | 2,774,980 | $30.55M | Insider |
| Arch Venture Fund XIII LP | 7.54% | 1,848,755 | $20.35M | Insider |
| Cathy Friedman | 1.03% | 253,188 | $2.79M | Insider |